Liquid Biopsy for Cancer Management: a Revolutionary but Still Limited New Tool for Precision Medicine

Overview

Journal Adv Lab Med

Publisher De Gruyter

Specialty Biochemistry

Date 2023 Jun 26

PMID 37361495

Authors

Maria Arechederra

Matias A Avila

Carmen Berasain

Affiliations

Soon will be listed here.

Abstract

The term liquid biopsy is used in contraposition to the traditional "solid" tissue biopsy. In the oncology field it has opened a new plethora of clinical opportunities as tumor-derived material is shedded into the different biofluids from where it can be isolated and analyzed. Common biofluids include blood, urine, saliva, cerebrospinal fluid (CSF), pleural effusion or bile. Starting from these biological specimens several analytes can be isolated, among which we will review the most widely used: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), proteins, metabolites, and exosomes. Regarding the nature of the biomarkers it will depend on the analyte, the type of tumor and the clinical application of the liquid biopsy and it includes, somatic point mutations, deletions, amplifications, gene-fusions, DNA-methylated marks, tumor-specific miRNAs, proteins or metabolites. Here we review the characteristics of the analytes and the methodologies used for their isolation. We also describe the applications of the liquid biopsy in the management of patients with cancer, from the early detection of cancers to treatment guidance in patients with advanced tumors. Finally, we also discuss some current limitations and still open questions.

Citing Articles

Toward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities.

Katopodi X, Begik O, Novoa E Nucleic Acids Res. 2025; 53(5).

PMID: 40057374 PMC: 11890063. DOI: 10.1093/nar/gkaf128.

Hydrogel-based technologies in liquid biopsy for the detection of circulating clinical markers: challenges and prospects.

Kim Y, Min J Anal Bioanal Chem. 2023; 416(9):2065-2078.

PMID: 37963993 DOI: 10.1007/s00216-023-05025-7.

Current Status and Emerging Trends in Colorectal Cancer Screening and Diagnostics.

Beniwal S, Lamo P, Kaushik A, Lorenzo-Villegas D, Liu Y, MohanaSundaram A Biosensors (Basel). 2023; 13(10).

PMID: 37887119 PMC: 10605407. DOI: 10.3390/bios13100926.

Liquid biopsy. A challenge for clinical laboratories.

Jimenez W Adv Lab Med. 2023; 1(3):20200055.

PMID: 37361499 PMC: 10197807. DOI: 10.1515/almed-2020-0055.

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.

Bozyk A, Nicos M Life (Basel). 2022; 12(10).

PMID: 36295075 PMC: 9604747. DOI: 10.3390/life12101640.

References

Lamb Y, Dhillon S . Epi proColon 2.0 CE: A Blood-Based Screening Test for Colorectal Cancer. Mol Diagn Ther. 2017; 21(2):225-232. DOI: 10.1007/s40291-017-0259-y. View

Elazezy M, Joosse S . Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018; 16:370-378. PMC: 6197739. DOI: 10.1016/j.csbj.2018.10.002. View

Yu M, Bardia A, Wittner B, Stott S, Smas M, Ting D . Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339(6119):580-4. PMC: 3760262. DOI: 10.1126/science.1228522. View

Torrano V, Royo F, Peinado H, Loizaga-Iriarte A, Unda M, Falcon-Perez J . Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. Curr Opin Pharmacol. 2016; 29:47-53. PMC: 4992611. DOI: 10.1016/j.coph.2016.06.003. View

Patel J . Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives. Pharmgenomics Pers Med. 2016; 9:65-77. PMC: 4948716. DOI: 10.2147/PGPM.S62918. View

Aceto N, Bardia A, Miyamoto D, Donaldson M, Wittner B, Spencer J . Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014; 158(5):1110-1122. PMC: 4149753. DOI: 10.1016/j.cell.2014.07.013. View

Kolinsky M, Stoecklein N, Lambros M, Gil V, Nava Rodrigues D, Carreira S . Genetic Analysis of Circulating Tumour Cells. Recent Results Cancer Res. 2019; 215:57-76. DOI: 10.1007/978-3-030-26439-0_3. View

Yu M . Circulating cell-free mitochondrial DNA as a novel cancer biomarker: opportunities and challenges. Mitochondrial DNA. 2012; 23(5):329-32. DOI: 10.3109/19401736.2012.696625. View

. ClonoSEQ Cleared for Residual Cancer Testing. Cancer Discov. 2018; 8(12):OF6. DOI: 10.1158/2159-8290.CD-NB2018-136. View

10.

De Rubis G, Rajeev Krishnan S, Bebawy M . Liquid Biopsies in Cancer Diagnosis, Monitoring, and Prognosis. Trends Pharmacol Sci. 2019; 40(3):172-186. DOI: 10.1016/j.tips.2019.01.006. View

11.

Bhardwaj M, Gies A, Weigl K, Tikk K, Benner A, Schrotz-King P . Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. Cancers (Basel). 2019; 11(10). PMC: 6826652. DOI: 10.3390/cancers11101426. View

12.

Wang W, Peng J, Li X, Wang A, Bie Y, Shi L . Survival Mechanisms and Influence Factors of Circulating Tumor Cells. Biomed Res Int. 2018; 2018:6304701. PMC: 6236925. DOI: 10.1155/2018/6304701. View

13.

Markus H, Contente-Cuomo T, Farooq M, Liang W, Borad M, Sivakumar S . Evaluation of pre-analytical factors affecting plasma DNA analysis. Sci Rep. 2018; 8(1):7375. PMC: 5943304. DOI: 10.1038/s41598-018-25810-0. View

14.

Suo Y, Xie C, Zhu X, Fan Z, Yang Z, He H . Proportion of circulating tumor cell clusters increases during cancer metastasis. Cytometry A. 2016; 91(3):250-253. DOI: 10.1002/cyto.a.23037. View

15.

de Wit S, van Dalum G, Terstappen L . Detection of circulating tumor cells. Scientifica (Cairo). 2014; 2014:819362. PMC: 4124199. DOI: 10.1155/2014/819362. View

16.

Morbelli S, Alama A, Ferrarazzo G, Coco S, Genova C, Rijavec E . Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer: F-FDG PET/CT Study. J Nucl Med. 2017; 58(11):1764-1769. DOI: 10.2967/jnumed.117.193201. View

17.

Harouaka R, Nisic M, Zheng S . Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013; 18(6):455-68. PMC: 3830628. DOI: 10.1177/2211068213494391. View

18.

McGranahan N, Swanton C . Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628. DOI: 10.1016/j.cell.2017.01.018. View

19.

Toss A, Mu Z, Fernandez S, Cristofanilli M . CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med. 2014; 2(11):108. PMC: 4245508. DOI: 10.3978/j.issn.2305-5839.2014.09.06. View

20.

Gossett D, Tse H, Lee S, Ying Y, Lindgren A, Yang O . Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proc Natl Acad Sci U S A. 2012; 109(20):7630-5. PMC: 3356639. DOI: 10.1073/pnas.1200107109. View